BioSpace News Archive

The GENOSYL® DS facilitates patient treatment in interhospital and intrahospital transport, and in diverse diagnostic and imaging settings, representing the broadest FDA approved label in the industry allowing use in the Acute-care Setting including MRI, Ground, Fixed Wing and Rotary Transport.

Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been dosed in its Phase 2 clinical trial evaluating ecopipam, the company’s investigational medicine, for the treatment of childhood-onset fluency disorder, or “stuttering.”

CorVent Medical, a Coridea portfolio company focused on developing smart, reusable, lifesaving ventilators for critical care, announced today an agreement with Siemens Healthineers for the U.S. distribution of the RESPOND-19™ Ventilator to their network of hospital, healthcare system, and government customers.

− If approved, TAK-721 will be the first FDA-approved treatment for the chronic inflammatory disease; Takeda plans to use the trade name Eohilia (budesonide oral suspension)

Nektar Therapeutics (NASDAQ:NKTR) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar’s investigational IL-15 pathway agonist, in patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) at the START Center for Cancer Care in San Antonio, TX.

The Gerontological Society of America (GSA) 2020 Annual Scientific Meeting, held November 4-7, 2020, unveiled promising research on cellular decline and the role of cellular nutrients to support mitochondrial health during aging.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19.

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical evaluation of axitinib.

Jaguar Health Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) issued a reminder today that Company management is hosting an investor call on Thursday, December 17th at 8:30 a.m. Eastern Standard Time

Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that Klisyri® (tirbanibulin) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK) of the face or scalp